This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Cinqaero
  • /
  • A Study to Evaluate the Efficacy and Safety of Res...
Clinical trial

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Read time: 3 mins
Last updated:1st Feb 2011
Identifier: NCT01270464

The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma as assessed by the overall change from baseline in forced expiratory volume in 1 second (FEV1).

Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Enrollment: 315
Study Start Date: February 2011
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)

Arms:
- Placebo Comparator: Placebo
- Experimental: Reslizumab - 0.3 mg/kg
- Experimental: Reslizumab - 3.0 mg/kg


Related journal: Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.

Category Value
Date last updated at source 2016-03-28
Study type(s) Interventional
Expected enrolment 315
Study start date 2011-02-01
Estimated primary completion date 2013-09-01

View full details